BACKGROUND:Musculoskeletal disorders (MSDs) are a frequent cause of work disability, accounting for productivity losses in industrialized societies equivalent to 1.3% of the U.S. gross national product. OBJECTIVE: To evaluate whether a population-based clinical program offered to patients with recent-onset work disability caused by MSDs is cost-effective. DESIGN: Randomized, controlled intervention study. The inclusion and follow-up periods each lasted 12 months. SETTING: Three health districts in Madrid, Spain. PATIENTS: All patients with MSD-related temporary work disability in 1998 and 1999. INTERVENTION: The control group received standard primary care management, with referral to specialized care if needed. The intervention group received a specific program, administered by rheumatologists, in which care was delivered during regular visits and included 3 main elements: education, protocol-based clinical management, and administrative duties. MEASUREMENTS: Efficacy variables were 1) days of temporary work disability and 2) number of patients with permanent work disability. All analyses were done on an intention-to-treat basis. RESULTS:1,077 patients were included in the study, 7805 in the control group and 5272 in the intervention group, generating 16,297 episodes of MSD-related temporary work disability. These episodes were shorter in the intervention group than in the control group (mean, 26 days compared with 41 days; P < 0.001), and the groups had similar numbers of episodes per patient. Fewer patients received long-term disability compensation in the intervention group (n = 38 [0.7%]) than in the control group (n = 99 [1.3%]) (P < 0.005). Direct and indirect costs were lower in the intervention group than in the control group. To save 1 day of temporary work disability, 6.00 dollars had to be invested in the program. Each dollar invested generated a benefit of 11.00 dollars. The program's net benefit was in excess of 5 million dollars. LIMITATIONS: The study was unblinded. CONCLUSIONS: Implementation of the program, offered to the general population, improves short- and long-term work disability outcomes and is cost-effective.
RCT Entities:
BACKGROUND:Musculoskeletal disorders (MSDs) are a frequent cause of work disability, accounting for productivity losses in industrialized societies equivalent to 1.3% of the U.S. gross national product. OBJECTIVE: To evaluate whether a population-based clinical program offered to patients with recent-onset work disability caused by MSDs is cost-effective. DESIGN: Randomized, controlled intervention study. The inclusion and follow-up periods each lasted 12 months. SETTING: Three health districts in Madrid, Spain. PATIENTS: All patients with MSD-related temporary work disability in 1998 and 1999. INTERVENTION: The control group received standard primary care management, with referral to specialized care if needed. The intervention group received a specific program, administered by rheumatologists, in which care was delivered during regular visits and included 3 main elements: education, protocol-based clinical management, and administrative duties. MEASUREMENTS: Efficacy variables were 1) days of temporary work disability and 2) number of patients with permanent work disability. All analyses were done on an intention-to-treat basis. RESULTS: 1,077 patients were included in the study, 7805 in the control group and 5272 in the intervention group, generating 16,297 episodes of MSD-related temporary work disability. These episodes were shorter in the intervention group than in the control group (mean, 26 days compared with 41 days; P < 0.001), and the groups had similar numbers of episodes per patient. Fewer patients received long-term disability compensation in the intervention group (n = 38 [0.7%]) than in the control group (n = 99 [1.3%]) (P < 0.005). Direct and indirect costs were lower in the intervention group than in the control group. To save 1 day of temporary work disability, 6.00 dollars had to be invested in the program. Each dollar invested generated a benefit of 11.00 dollars. The program's net benefit was in excess of 5 million dollars. LIMITATIONS: The study was unblinded. CONCLUSIONS: Implementation of the program, offered to the general population, improves short- and long-term work disability outcomes and is cost-effective.
Authors: Arianne P Verhagen; Sita M A Bierma-Zeinstra; Alex Burdorf; Siobhán M Stynes; Henrica C W de Vet; Bart W Koes Journal: Cochrane Database Syst Rev Date: 2013-12-12
Authors: Nicole Vogel; Stefan Schandelmaier; Thomas Zumbrunn; Shanil Ebrahim; Wout El de Boer; Jason W Busse; Regina Kunz Journal: Cochrane Database Syst Rev Date: 2017-03-30
Authors: Craig Conlon; Steven Asch; Mark Hanson; Andrew Avins; Barbara Levitan; Carol Roth; Michael Robbins; Michael Dworsky; Seth Seabury; Teryl Nuckols Journal: Perm J Date: 2016-10-03
Authors: Leticia Leon; Juan Angel Jover; Estibaliz Loza; Maria Victoria Zunzunegui; Cristina Lajas; Cristina Vadillo; Oscar Fontsere; Luis Rodriguez-Rodriguez; Cristina Martinez; Benjamin Fernandez-Gutierrez; Lydia Abasolo Journal: Rheumatol Int Date: 2013-01-11 Impact factor: 2.631
Authors: Teryl Nuckols; Philip Harber; Karl Sandin; Douglas Benner; Haoling Weng; Rebecca Shaw; Anne Griffin; Steven Asch Journal: J Occup Rehabil Date: 2011-03
Authors: Harald Leiss; Miriam Hucke; Manuel Bécède; Veronika Machold-Fabrizii; Josef S Smolen; Klaus P Machold Journal: Sci Rep Date: 2019-04-10 Impact factor: 4.379